EGFR and neoplasm: In the present work, BetA's anticancer activity against drug-resistant tumor cell lines was studied, in which either MDR-conferring ABC-transporters (P-glycoprotein, BCRP, and ABCB5) or mutation-activated EGFR were overexpressed.